Record Details

‘TRAIL’ of targeted colorectal cancer therapy

Online Publishing @ NISCAIR

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement ‘TRAIL’ of targeted colorectal cancer therapy
 
Added Entry - Uncontrolled Name Jain, Nishakumari
Parikshit, Parikshit
Ranjan Bhuyan, Nihar
Kuppusamy, Gowthamarajan
 
Uncontrolled Index Term Adenosquamous; Apoptosis; Capsazepine; Carcinoma; Doxorubicin; Necrosis; Protein kinase
 
Summary, etc. TRAIL, a tumor necrosis factor-related apoptosis-inducing ligand is a member of the tumor necrosis factor (TNF) superfamily, which is a cytokine that has shown a particularly precise and selective affinity towards death receptors that are overexpressed in cancer cells. While leaving the normal cells intact and unharmed, due to this property it has been the ligand of choice for highly precise cancer chemotherapeutic delivery system development. On numerous occasions, TRAIL has been used singularly and in combination with other drugs. It was observed that TRAIL had a tendency to be susceptible in terms of the cancer cells developing resistance against it. So TRAIL monotherapy was a bit of a rough patch for the molecule to become successful in the chemotherapy universe, however the conjugations and synergistic actions of TRAIL opened up new horizons which are discussed in this review with specific interest on colorectal cancer (CRC).
 
Publication, Distribution, Etc. Indian Journal of Biochemistry and Biophysics (IJBB)
2023-01-24 00:00:00
 
Electronic Location and Access application/pdf
http://op.niscair.res.in/index.php/IJBB/article/view/70737
 
Data Source Entry Indian Journal of Biochemistry and Biophysics (IJBB); IJBB Vol. 60 (2) [February 2023]
 
Language Note en